Olr382 inhibitors represent a unique and evolving class of chemical compounds that are characterized by their specific ability to modulate the activity of the olfactory receptor Olr382, a member of the G-protein coupled receptor (GPCR) superfamily. Olr382, like other olfactory receptors, plays a critical role in detecting and responding to odorant molecules. The inhibition of this receptor can be studied in the context of its molecular interaction with various ligands, allowing researchers to explore the nuanced mechanisms by which olfactory signals are modulated at the cellular level. The inhibitors are often designed or identified through high-throughput screening, followed by structural optimization to enhance selectivity and affinity for Olr382. These compounds are crucial in unraveling the molecular details of odorant-receptor binding and signal transduction pathways, providing insight into the broader family of olfactory receptors and their roles in sensory biology.
The chemical structure of Olr382 inhibitors is typically optimized for high receptor binding specificity and minimal off-target effects, which is critical for studying the isolated functions of Olr382. Structural features often include specific aromatic or heteroaromatic moieties that interact with key amino acid residues within the receptor's binding pocket. Detailed studies, including crystallography or molecular dynamics simulations, are frequently employed to map out these interactions at an atomic level, offering a clear picture of how these inhibitors achieve their selective binding. Additionally, the pharmacokinetic properties of these inhibitors, such as their metabolic stability, lipophilicity, and membrane permeability, are meticulously characterized to ensure they effectively reach their target within cellular environments. The study of Olr382 inhibitors, therefore, not only contributes to our understanding of olfactory receptor functionality but also provides a framework for exploring the broader roles of GPCRs in various biological processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Multi-targeted receptor tyrosine kinase (RTK) inhibitor, potentially disrupts VEGF and PDGF signaling pathways. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor, potentially modulates cytokine and growth factor signaling crucial in hematologic malignancies. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor, potentially disrupts the MAPK/ERK pathway, crucial in melanoma and other cancers. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, potentially affects NF-κB signaling and cell cycle regulation. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Bruton's tyrosine kinase (BTK) inhibitor, potentially alters B-cell receptor signaling in lymphomas. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
BRAF inhibitor, potentially targets the MAPK/ERK pathway in melanoma with BRAF V600 mutations. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
ALK inhibitor, potentially targets ALK-positive non-small cell lung cancer by disrupting ALK-mediated signaling. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
MEK1/2 inhibitor, potentially affects the RAS/RAF/MEK/ERK pathway in various cancers. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor, potentially regulates cell cycle progression in breast cancer. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Multi-kinase inhibitor, potentially affects MET, VEGFR, and AXL signaling in medullary thyroid cancer. | ||||||